Eintrag weiter verarbeiten
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Journal of Clinical Oncology, 23, 2005, 3, S. 585-590 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Hotte, Sébastien J. Winquist, Eric W. Lamont, Elizabeth MacKenzie, Mary Vokes, Everett Chen, Eric X. Brown, Shirley Pond, Gregory R. Murgo, Anthony Siu, Lillian L. Hotte, Sébastien J. Winquist, Eric W. Lamont, Elizabeth MacKenzie, Mary Vokes, Everett Chen, Eric X. Brown, Shirley Pond, Gregory R. Murgo, Anthony Siu, Lillian L. |
|---|---|
| author |
Hotte, Sébastien J. Winquist, Eric W. Lamont, Elizabeth MacKenzie, Mary Vokes, Everett Chen, Eric X. Brown, Shirley Pond, Gregory R. Murgo, Anthony Siu, Lillian L. |
| spellingShingle |
Hotte, Sébastien J. Winquist, Eric W. Lamont, Elizabeth MacKenzie, Mary Vokes, Everett Chen, Eric X. Brown, Shirley Pond, Gregory R. Murgo, Anthony Siu, Lillian L. Journal of Clinical Oncology Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study Cancer Research Oncology |
| author_sort |
hotte, sébastien j. |
| spelling |
Hotte, Sébastien J. Winquist, Eric W. Lamont, Elizabeth MacKenzie, Mary Vokes, Everett Chen, Eric X. Brown, Shirley Pond, Gregory R. Murgo, Anthony Siu, Lillian L. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2005.06.125 <jats:sec><jats:title>Purpose</jats:title><jats:p> This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit. A high level of c-kit expression has been identified in more than 90% of ACCs. Imatinib specifically inhibits autophosphorylation of the bcr-abl, platelet-derived growth factor receptor beta, and c-kit tyrosine kinases. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> In a single-arm, two-stage, phase II clinical trial, adult patients with unresectable or metastatic ACC measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Sixteen patients have been enrolled onto the study; 10 were female. Median age was 47 years (range, 31 to 69 years). Median Eastern Cooperative Oncology Group performance status was 1 (range, 0 to 2). Fourteen patients had lung metastases, 14 had prior radiotherapy, and six had prior chemotherapy. Toxicities occurring in at least 50% of patients included fatigue, nausea, vomiting, diarrhea, anorexia, edema, dyspnea, and/or headache, usually of mild to moderate severity. In 15 patients assessable for response, no objective responses have been observed. Nine patients had stable disease as best response. Six patients had progressive disease after two cycles. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Because of the lack of activity, the study has been stopped after the first stage and additional evaluation of imatinib in this population is not warranted. Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC. Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients. </jats:p></jats:sec> Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2005.06.125 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4wNi4xMjU |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4wNi4xMjU |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2005 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2005 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
hotte2005imatinibmesylateinpatientswithadenoidcysticcancersofthesalivaryglandsexpressingckitaprincessmargarethospitalphaseiiconsortiumstudy |
| publishDateSort |
2005 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_unstemmed |
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_full |
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_fullStr |
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_full_unstemmed |
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_short |
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_sort |
imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a princess margaret hospital phase ii consortium study |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2005.06.125 |
| publishDate |
2005 |
| physical |
585-590 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit. A high level of c-kit expression has been identified in more than 90% of ACCs. Imatinib specifically inhibits autophosphorylation of the bcr-abl, platelet-derived growth factor receptor beta, and c-kit tyrosine kinases. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> In a single-arm, two-stage, phase II clinical trial, adult patients with unresectable or metastatic ACC measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Sixteen patients have been enrolled onto the study; 10 were female. Median age was 47 years (range, 31 to 69 years). Median Eastern Cooperative Oncology Group performance status was 1 (range, 0 to 2). Fourteen patients had lung metastases, 14 had prior radiotherapy, and six had prior chemotherapy. Toxicities occurring in at least 50% of patients included fatigue, nausea, vomiting, diarrhea, anorexia, edema, dyspnea, and/or headache, usually of mild to moderate severity. In 15 patients assessable for response, no objective responses have been observed. Nine patients had stable disease as best response. Six patients had progressive disease after two cycles. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Because of the lack of activity, the study has been stopped after the first stage and additional evaluation of imatinib in this population is not warranted. Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC. Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients. </jats:p></jats:sec> |
| container_issue |
3 |
| container_start_page |
585 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
23 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347450106707974 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:55:28.959Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Imatinib+Mesylate+in+Patients+With+Adenoid+Cystic+Cancers+of+the+Salivary+Glands+Expressing+c-kit%3A+A+Princess+Margaret+Hospital+Phase+II+Consortium+Study&rft.date=2005-01-20&genre=article&issn=1527-7755&volume=23&issue=3&spage=585&epage=590&pages=585-590&jtitle=Journal+of+Clinical+Oncology&atitle=Imatinib+Mesylate+in+Patients+With+Adenoid+Cystic+Cancers+of+the+Salivary+Glands+Expressing+c-kit%3A+A+Princess+Margaret+Hospital+Phase+II+Consortium+Study&aulast=Siu&aufirst=Lillian+L.&rft_id=info%3Adoi%2F10.1200%2Fjco.2005.06.125&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347450106707974 |
| author | Hotte, Sébastien J., Winquist, Eric W., Lamont, Elizabeth, MacKenzie, Mary, Vokes, Everett, Chen, Eric X., Brown, Shirley, Pond, Gregory R., Murgo, Anthony, Siu, Lillian L. |
| author_facet | Hotte, Sébastien J., Winquist, Eric W., Lamont, Elizabeth, MacKenzie, Mary, Vokes, Everett, Chen, Eric X., Brown, Shirley, Pond, Gregory R., Murgo, Anthony, Siu, Lillian L., Hotte, Sébastien J., Winquist, Eric W., Lamont, Elizabeth, MacKenzie, Mary, Vokes, Everett, Chen, Eric X., Brown, Shirley, Pond, Gregory R., Murgo, Anthony, Siu, Lillian L. |
| author_sort | hotte, sébastien j. |
| container_issue | 3 |
| container_start_page | 585 |
| container_title | Journal of Clinical Oncology |
| container_volume | 23 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit. A high level of c-kit expression has been identified in more than 90% of ACCs. Imatinib specifically inhibits autophosphorylation of the bcr-abl, platelet-derived growth factor receptor beta, and c-kit tyrosine kinases. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> In a single-arm, two-stage, phase II clinical trial, adult patients with unresectable or metastatic ACC measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Sixteen patients have been enrolled onto the study; 10 were female. Median age was 47 years (range, 31 to 69 years). Median Eastern Cooperative Oncology Group performance status was 1 (range, 0 to 2). Fourteen patients had lung metastases, 14 had prior radiotherapy, and six had prior chemotherapy. Toxicities occurring in at least 50% of patients included fatigue, nausea, vomiting, diarrhea, anorexia, edema, dyspnea, and/or headache, usually of mild to moderate severity. In 15 patients assessable for response, no objective responses have been observed. Nine patients had stable disease as best response. Six patients had progressive disease after two cycles. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Because of the lack of activity, the study has been stopped after the first stage and additional evaluation of imatinib in this population is not warranted. Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC. Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2005.06.125 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4wNi4xMjU |
| imprint | American Society of Clinical Oncology (ASCO), 2005 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2005 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T17:55:28.959Z |
| match_str | hotte2005imatinibmesylateinpatientswithadenoidcysticcancersofthesalivaryglandsexpressingckitaprincessmargarethospitalphaseiiconsortiumstudy |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 585-590 |
| publishDate | 2005 |
| publishDateSort | 2005 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Hotte, Sébastien J. Winquist, Eric W. Lamont, Elizabeth MacKenzie, Mary Vokes, Everett Chen, Eric X. Brown, Shirley Pond, Gregory R. Murgo, Anthony Siu, Lillian L. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2005.06.125 <jats:sec><jats:title>Purpose</jats:title><jats:p> This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit. A high level of c-kit expression has been identified in more than 90% of ACCs. Imatinib specifically inhibits autophosphorylation of the bcr-abl, platelet-derived growth factor receptor beta, and c-kit tyrosine kinases. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> In a single-arm, two-stage, phase II clinical trial, adult patients with unresectable or metastatic ACC measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Sixteen patients have been enrolled onto the study; 10 were female. Median age was 47 years (range, 31 to 69 years). Median Eastern Cooperative Oncology Group performance status was 1 (range, 0 to 2). Fourteen patients had lung metastases, 14 had prior radiotherapy, and six had prior chemotherapy. Toxicities occurring in at least 50% of patients included fatigue, nausea, vomiting, diarrhea, anorexia, edema, dyspnea, and/or headache, usually of mild to moderate severity. In 15 patients assessable for response, no objective responses have been observed. Nine patients had stable disease as best response. Six patients had progressive disease after two cycles. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Because of the lack of activity, the study has been stopped after the first stage and additional evaluation of imatinib in this population is not warranted. Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC. Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients. </jats:p></jats:sec> Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study Journal of Clinical Oncology |
| spellingShingle | Hotte, Sébastien J., Winquist, Eric W., Lamont, Elizabeth, MacKenzie, Mary, Vokes, Everett, Chen, Eric X., Brown, Shirley, Pond, Gregory R., Murgo, Anthony, Siu, Lillian L., Journal of Clinical Oncology, Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study, Cancer Research, Oncology |
| title | Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_full | Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_fullStr | Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_full_unstemmed | Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_short | Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| title_sort | imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a princess margaret hospital phase ii consortium study |
| title_unstemmed | Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2005.06.125 |